Dr. Laurence Albiges, Oncologist, head of the GU Tumor Board at the Gustave Roussy speaking during ESMO 2016 about how immunotherapy has had an impact on the field of renal cell carcinoma (RCC). Watch the video.
Results from the phase II CABOSUN clinical trial, showing cabozantinib to be superior to sunitinib as first-line treatment for advanced kidney cancer, were presented at the European Society for Medical Oncology (ESMO) congress in Copenhagen this week. Read more
Results from the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for relapse. Read more
Dose escalation of tyrosine kinase inhibitors (TKIs) after disease progression in patients with metastatic renal cell carcinoma (mRCC) can lead to a decrease in tumour burden and extend duration of therapy, according to a study. Read more
Immuno-oncology (IO) therapy is a new (and old) way to treat cancer by activating your immune system in the hope that it will attack your tumour. Our sister site ‘10-for-IO’ is a central resource for patient organisations to access information about immuno-oncology specifically as it applies to renal cell carcinoma. Click here for more information.
Novel targeted and immunological therapies may help improve the outlook for patients with renal cell carcinoma (RCC), according to Dr Basma Greef, of the department of oncology at the Cambridge University Hospitals NHS Foundation Trust in the United Kingdom. She and her co-author, professor Tim Eisen, published an article in the British Journal of Cancer suggesting that researchers are introducing a renaissance of immunotherapy in the treatment of RCC. Read more